JCS/T2D - A Diabetes Journey
LightNews LightNews
banner
jcst2d.bsky.social
JCS/T2D - A Diabetes Journey
@jcst2d.bsky.social
18 followers 1 following 130 posts
I draw on my professional expertise in data analysis and my personal health journey with Type 2 Diabetes to make technical information about T2D and obesity more accessible.
Posts Replies Media Videos
jcst2d.bsky.social
Novo Nordisk files NDA for a higher 7.2 mg dose of Wegovy, supported by STEP UP trial results and an accelerated FDA review.

jcst2d.com/index.php/ne...

#Wegovy #Semaglutide #ObesityCare #GLP1 #ClinicalTrials
Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.
November 28, 2025 at 4:19 PM
jcst2d.bsky.social
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes, with meaningful HbA1c and weight reductions. EVOKE findings add valuable insight for Alzheimer’s research.

jcst2d.com/index.php/ne...

#Diabetes #ObesityCare #GLP1 #Amycretin #ClinicalTrials
Martin Holst Lange, MD, PhD. Image courtesy of Novo Nordisk.
November 26, 2025 at 12:38 AM
jcst2d.bsky.social
Oral semaglutide did not slow Alzheimer’s progression in the EVOKE trials, despite favorable biomarker shifts.

jcst2d.com/index.php/ne...

#Semaglutide #EVOKETrials #Alzheimers #ClinicalTrialResults #MetabolicHealth
Novo Nordisk Flags. Courtesy of Novo Nordisk.
November 24, 2025 at 8:41 PM
jcst2d.bsky.social
Why Wegovy isn’t headed for OTC status—what the sources really say, why GLP-1 therapies don’t fit OTC criteria & why the conversation matters in obesity treatment.

jcst2d.com/index.php/ar...

#Wegovy #GLP1 #ObesityTreatment #DrugRegulation #MedicationSafety
Wegovy 2.4 mg pens
November 23, 2025 at 3:27 PM
jcst2d.bsky.social
Zealand Pharma paused dapiglutide after early data showed no advantage over newer incretin therapies. Focus shifts to programs with stronger potential.

jcst2d.com/index.php/ne...

#ObesityTreatment #GLP1 #Incretins #MetabolicHealth
Zealand Pharma logo
November 15, 2025 at 2:47 PM
jcst2d.bsky.social
Innovent’s mazdutide outperformed semaglutide in a key Phase 3 trial for type 2 diabetes and obesity. Expert commentary highlights trial design, metabolic mechanisms and next-gen incretin therapy questions.

jcst2d.com/index.php/ne...

#Mazdutide #Semaglutide #T2D #Obesity #IncretinTherapy
Innovent’s Mazdutide injection packaging and pens in 2 mg, 4 mg, and 6 mg doses, shown with labeled boxes and corresponding injection pens for type 2 diabetes and obesity treatment.
October 28, 2025 at 10:36 PM
jcst2d.bsky.social
New Lancet analysis shows semaglutide lowers major cardiovascular events by 20%, even in patients who lose little weight—highlighting benefits beyond fat loss.

jcst2d.com/index.php/ne...

#Semaglutide #SELECTTrial #HeartHealth #GLP1 #ObesityCare
Wegovy (semaglutide) 2.4 mg Pens
October 26, 2025 at 6:53 PM
jcst2d.bsky.social
Terns Pharmaceuticals has ended development of its oral GLP-1 obesity drug TERN-601 after modest Phase 2 results and new safety concerns. The company shifts focus to oncology with TERN-701 for leukemia.

jcst2d.com/index.php/ne...

#TernsPharma #Obesity #GLP1 #ClinicalTrials #DrugDevelopment
Terns Pharmaceuticals Logo
October 22, 2025 at 10:37 PM
jcst2d.bsky.social
FDA approves Novo Nordisk’s Rybelsus (oral semaglutide) to cut major heart risks in adults with type 2 diabetes. The SOUL trial showed a 14% reduction in cardiovascular events.

jcst2d.com/index.php/ne...

#Type2Diabetes #Rybelsus #HeartHealth #NovoNordisk
Oral semaglutide (Rybelsus). Courtesy of Novo Nordisk.
October 20, 2025 at 10:42 PM
jcst2d.bsky.social
Lilly’s oral GLP-1 orforglipron outshines Farxiga in Type 2 diabetes—a1C, weight, and heart metrics all improved.

jcst2d.com/index.php/ne...

#orforglipron #Farxiga #Type2Diabetes
Eli Lilly logo
October 17, 2025 at 10:38 PM
jcst2d.bsky.social
Novo Nordisk has resubmitted Awiqli® (insulin icodec) to the FDA for type 2 diabetes, offering fewer injections and a simpler treatment routine.

jcst2d.com/index.php/ne...

#NovoNordisk #Awiqli #Type2Diabetes #Insulin #DiabetesResearch
Awiqli® (insulin icodec) pen. Courtesy of Novo Nordisk Canada.
September 30, 2025 at 12:48 AM
jcst2d.bsky.social
Dexcom introduced Smart Basal at EASD 2025, a G7 app feature under FDA and CE Mark review that simplifies basal insulin initiation and adjustment.

jcst2d.com/index.php/ne...

#Dexcom #SmartBasal #EASD2025 #DiabetesCare #CGM
Illustration from the Dexcom G7 app showing the Dexcom Smart Basal feature. A hand holds a smartphone with a glucose trend line on the screen, next to a vial of insulin highlighted in a green circle. Text explains that glucose data is used to recommend a daily long-acting insulin dose.
September 22, 2025 at 11:21 PM
jcst2d.bsky.social
Novo Nordisk’s INFORM survey shows people on Wegovy® had 46% less “food noise,” plus boosts in mental health, habits & lifestyle. Sample size (550, mostly women, avg age 53) may limit generalizability.

jcst2d.com/index.php/ne...

#Wegovy #ObesityCare #PatientExperience
Novo Nordisk Flags. Courtesy of Novo Nordisk.
September 21, 2025 at 8:12 PM
jcst2d.bsky.social
Lilly’s oral GLP-1, orforglipron, delivers strong Phase 3 results with significant weight loss in obesity, superior A1C and weight outcomes vs oral semaglutide in type 2 diabetes.

jcst2d.com/index.php/ne...

#Orforglipron #ObesityTreatment #Type2Diabetes #WeightLoss
Eli Lilly Logo
September 21, 2025 at 6:31 PM
jcst2d.bsky.social
CGMs, wearables, biobanks, and registries show how personalized medicine in the Nordics connects to diabetes care and more broadly to medical care more broadly.

jcst2d.com/index.php/ar...

#Diabetes #CGM #HealthcareData #PersonalisedMedicine
Certificate of completion from Coursera for the course ‘Personalised Medicine from a Nordic Perspective,’ authorized by the University of Copenhagen and the University of Iceland, awarded to Jeffrey Smith on September 12, 2025.
September 14, 2025 at 6:13 PM
jcst2d.bsky.social
Novonesis and Novo Nordisk team up to explore how gut-targeted synbiotics might support metabolic health and tackle obesity and related conditions.

jcst2d.com/index.php/ne...

#Novonesis #NovoNordisk #GutMicrobiome #MetabolicHealth #ObesityPrevention
Logos of Novo Nordisk and Novonesis displayed over a blue-toned background of magnified gut microbiome imagery. Courtesy of Novonesis.
September 8, 2025 at 5:58 PM
jcst2d.bsky.social
CVS Caremark faces a class-action lawsuit over dropping Zepbound in favor of Wegovy. Plaintiffs cite differences in indications, patient tolerability, and outcomes; experts point out why the two drugs may be complementary.

jcst2d.com/index.php/ne...

#CVSCaremark #Wegovy #Zepbound #GLP1 #HealthLaw
Zepbound (tirzepatide) 5 mg pen
September 7, 2025 at 3:09 PM
jcst2d.bsky.social
Lilly ends two phase 2 trials of oral GLP-1 naperiglipron in type 2 diabetes and healthy adults. A study in obesity continues into 2026. The move reflects the market’s obesity focus, but the drug’s future remains uncertain.

jcst2d.com/index.php/ne...

#GLP1 #Obesity #DiabetesCare #ClinicalTrials
Eli Lilly Logo
September 4, 2025 at 10:21 PM
jcst2d.bsky.social
Novo Nordisk’s Wegovy cut the risk of heart attack, stroke or death by 57% compared to tirzepatide in a real-world study of people with obesity and cardiovascular disease.

jcst2d.com/index.php/ne...

#Wegovy #Mounjaro #Cardiovascular #Obesity #Diabetes
Wegovy 0.25 mg semaglutide injection pen for subcutaneous use, white body with teal and white label and gray cap.
August 31, 2025 at 6:19 PM
jcst2d.bsky.social
Teva's generic Saxenda (liraglutide) wins FDA approval, after its Victoza generic in 2024. Obesity drug market could nearly triple by 2030 with access, affordability & generics driving growth.

jcst2d.com/index.php/ne...

#Teva #GenericSaxenda #ObesityTreatment #FDAApproval #AccessToMedications
Teva logo
August 29, 2025 at 9:12 PM
jcst2d.bsky.social
Novo Nordisk inks a $550M deal with Replicate Bioscience to develop self-replicating RNA (srRNA) therapies for obesity and type 2 diabetes. Durable effects at lower doses spark optimism.

jcst2d.com/index.php?vi...

#srRNA #NovoNordisk #ReplicateBioscience #Obesity #Diabetes
Replicate Bioscience Logo
August 29, 2025 at 11:47 AM
jcst2d.bsky.social
FDA expands Repatha access for adults with uncontrolled LDL-C at high cardiovascular risk—even without prior heart disease. For people with diabetes, this opens a new and effective treatment path.

jcst2d.com/index.php?vi...

#Repatha #Cholesterol #Diabetes #CardiovascularHealth #LDL
Amgen Logo
August 27, 2025 at 9:10 PM
jcst2d.bsky.social
Eli Lilly’s oral GLP-1 orforglipron posts successful Phase 3 results with 10.5 % weight loss and A1C reduction in obese and T2D patients. Analysts note its small-molecule cost edge over Novo’s semaglutide.

jcst2d.com/index.php?vi...

#orforglipron #Lilly #oralGLP1 #Phase3 #T2D
Eli Lilly Logo
August 26, 2025 at 11:42 PM
jcst2d.bsky.social
Signos announced FDA clearance for weight management, but records show only glucose monitoring was cleared, not weight loss claims. Learn what was actually approved.

jcst2d.com/index.php?vi...

#FDA #Signos #CGM #DiabetesTech
Yellow caution triangle with a white exclamation mark in the center.
August 21, 2025 at 11:20 PM
jcst2d.bsky.social
Novo Nordisk expands its $499 cash-pay option to Ozempic, offering U.S. patients with type 2 diabetes a lower-cost alternative and increasing pressure on rival Eli Lilly.

jcst2d.com/index.php?vi...

#Ozempic #Type2Diabetes #NovoNordisk #Semaglutide
Ozempic pens. Courtesy of Novo Nordisk.
August 18, 2025 at 10:14 PM